Trending NewsTrending NewsNASDAQ:VNDA Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis $4.00 +0.01 (+0.25%) Closing price 10/28/2026 04:00 PM EasternExtended Trading$4.21 +0.21 (+5.25%) As of 10/28/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Vanda Pharmaceuticals Stock (NASDAQ:VNDA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vanda Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.79▼$4.0850-Day Range$3.94▼$5.5752-Week Range$3.79▼$9.94Volume2.00 million shsAverage Volume1.49 million shsMarket Capitalization$241.85 millionP/E RatioN/ADividend YieldN/APrice Target$13.08Consensus RatingHold Company Overview Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, D.C., the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets. Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome. The company also markets Fanapt (iloperidone), an atypical antipsychotic used to treat schizophrenia in adults and approved for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. In addition to its commercial products, Vanda has pursued clinical development programs addressing disorders such as gastroparesis and other conditions involving sleep, circadian rhythms and the central nervous system. The company’s strategy centers on advancing therapies through clinical development and regulatory review while expanding the use of its approved medicines.AI Generated. May Contain Errors. Read More Vanda Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreVNDA MarketRank™: 3.490310077515 of 5 starsVanda Pharmaceuticals scored higher than 70% of companies evaluated by MarketBeat, and ranked 427th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingVanda Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialVanda Pharmaceuticals has a consensus price target of $13.08, representing about 227.1% upside from its current price of $4.00.Amount of Analyst CoverageVanda Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vanda Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vanda Pharmaceuticals are expected to grow in the coming year, from ($3.02) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vanda Pharmaceuticals is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vanda Pharmaceuticals is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vanda Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.39% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 8.31.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently increased by 6.10%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.90 News SentimentVanda Pharmaceuticals has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Vanda Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for VNDA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.70% of the stock of Vanda Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vanda Pharmaceuticals' insider trading history. Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VNDA Stock News HeadlinesVanda Pharmaceuticals Inc. reports third quarter 2026 financial results1 hour ago | msn.comVanda Pharmaceuticals (VNDA) Releases Q3 2026 Earnings: Revenue Plunges and Loss WidensOctober 28 at 4:50 PM | quiverquant.comQWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare. | Digest Publishing (Ad)Vanda Pharmaceuticals Reports Third Quarter 2026 Financial ResultsOctober 28 at 4:01 PM | prnewswire.comVanda Pharmaceuticals Announces Encouraging Data From NEREUS Phase 3 StudyOctober 28 at 9:07 AM | rttnews.comVanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial OutcomesOctober 27 at 2:31 PM | benzinga.comVanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial OutcomesOctober 27 at 2:13 PM | benzinga.comVanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced VomitingOctober 27 at 6:50 AM | prnewswire.comSee More Headlines VNDA Stock Analysis - Frequently Asked Questions How have VNDA shares performed this year? Vanda Pharmaceuticals' stock was trading at $8.82 at the beginning of the year. Since then, VNDA shares have decreased by 54.6% and is now trading at $4.00. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its earnings results on Wednesday, October, 28th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.31. The biopharmaceutical company had revenue of $1.61 million for the quarter, compared to analysts' expectations of $69.20 million. Vanda Pharmaceuticals had a negative trailing twelve-month return on equity of 49.81% and a negative net margin of 127.41%. Read the conference call transcript. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vanda Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Intel (INTC), Palantir Technologies (PLTR), Chevron (CVX) and Bristol Myers Squibb (BMY). Company Calendar Today10/28/2026Last Earnings10/28/2026Next Earnings (Estimated)10/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 VNDA's financial health is in the Red zone, according to TradeSmith. VNDA has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VNDA CIK1347178 Webwww.vandapharma.com Phone(202) 734-3400Fax202-296-1450Employees533Year Founded2002Price Target and Rating Average Price Target for Vanda Pharmaceuticals$13.08 High Price Target$20.00 Low Price Target$7.50 Potential Upside/Downside+227.1%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($4.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$220.47 million Net Margins-127.41% Pretax Margin-82.14% Return on Equity-49.81% Return on Assets-33.29% Debt Debt-to-Equity Ratio0.01 Current Ratio1.61 Quick Ratio1.60 Sales & Book Value Annual Sales$215.72 million Price / Sales1.12 Cash FlowN/A Price / Cash FlowN/A Book Value$5.54 per share Price / Book0.72Miscellaneous Outstanding Shares60,463,000Free Float53,993,000Market Cap$241.85 million OptionableOptionable Beta0.69 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:VNDA) was last updated on 10/28/2026 by MarketBeat.com Staff. From Our PartnersThe cash in your checking account has a problemThere's a pile of cash sitting in your checking account, earning next to nothing while you weigh your options....Counterflow | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
